Clinical trials: Antiviral
Venous System, Venous Access
A Retrospective, Observational, Monocenter, Study to Describe the Utilization and Overall Safety and Performance of POLYSITE®/SEESITE® Implantable Ports
This study is a retrospective, observational, monocenter case series. The purpose of this study is to collect clinical data to describe the use of POLYSITE® and SEESITE® devices and verify overall safety and performance.
- Conditions
- Venous System, Venous Access, Chemotherapy, Antibiotics
- Trial name
- NCT05519787
- Testing
- Central Veinous access devices' insertion
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Perouse Medical
Astrocytoma, Grade IV, Giant Cell Glioblastoma
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide
- Trial name
- CYNK001GBM01 (NCT04489420)
- Testing
- CYNK001-IV, CYNK001-IT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Celularity Incorporated
Antiviral Drugs
The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study
Tenofovir alafenamide (TAF) and entecavir (ETV) are the preferred agents in patients with predisposing factors for nephrotoxicity, but few studies to date have directly compared the renal safety of the two antiviral drugs in…
- Trial name
- NCT05453448
- Testing
- tenofovir alafenamide, Entecavir
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Xiangya Hospital of Central South University
HIV/AIDS, Antiviral Toxicity
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Increased comorbidities such as cardiovascular disease (CVD), are emerging problems in HIV infection but the mechanisms are unclear.
- Conditions
- HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
- Trial name
- UCLACAREMITO (NCT03251144)
- Testing
- Switch to E/C/FTC/TAF daily
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Chronic Hepatitis B, Mother-to-child Block
Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection
The effectiveness of mother-to-child block of CHB in pregnant women in the middle and later stages of pregnancy has been recognized by the guidelines.
- Conditions
- Chronic Hepatitis B, Mother-to-child Block, Antiviral Treatment
- Trial name
- NCT04507607
- Testing
- Tenofovir Alafenamide 25 MG
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Relapse
Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse
The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks from completion of therapy.
- Conditions
- Hepatitis C, Relapse, Antivirals
- Trial name
- NCT04662138
- Testing
- directly acting antivirals
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Liver Cirrhoses, Chronic Hepatitis c
Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin
Use of Ribavirin could affect hematologic profile of the patients negatively. With advent of new antiviral therapy, the preexisting hematologic changes may alter or corrected after treatment.
- Conditions
- Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals
- Trial name
- NCT03283176
- Testing
- Vitamin B12 and Folic Acid
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Hepatitis C, Chronic, Sustained Virological Response
Prediction of Liver-related Outcomes After HCV Cure
Objectives: To develop and validate a predictive model, applicable to daily practice, of liver complications emergence in hepatitis C virus (HCV)-infected patients and advanced fibrosis, who have achieved sustained viral response…
- Conditions
- Hepatitis C, Chronic, Sustained Virological Response, Direct-acting Antivirals, Hepatocellular Carcinoma
- Trial name
- NCT04460157
- Where
- Spain
- Volunteers
- 1,035 people
- Sponsor
- Hospital Universitario de Valme
HCV Related Liver Cirrhosis Direct Acting Antiviral Drugs
Quality of Life in Patients With HCV Related Liver Cirrhosis Before and After Direct Acting Antiviral Drugs
To evaluate the effects of DAAs on HRQL in patients with liver cirrhosis secondary to chronic HCV infection
- Trial name
- NCT03897608
- Testing
- short form 36
- Volunteers
- 50 people
- Sponsor
- Assiut University
Hepatitis C, Public Health
HCV RAS Testing in Public Health Programs
Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation.
- Conditions
- Hepatitis C, Public Health, Direct Acting Antiviral Agents, Resistance Associated Substitutions
- Trial name
- RAS-HCV (NCT04242433)
- Testing
- Direct Acting Antivirals
- Where
- 2 sites in India
- Volunteers
- 200 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Antiviral Drug
Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital
1. evaluation of glomerular filtration rate(eGFR)changes during HCV treatment with direct antiviral drugs according to 2018 guideline. 2.
- Trial name
- NCT03965286
- Testing
- DAAs
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults
This is a Phase I randomized, double blind, placebo controlled trial in up to 25 males and non-pregnant females, 18-45 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03473002
- Testing
- SeVRSV Vaccine
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Cirrhosis
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
The main risk factor for development of hepatocellular carcinoma (HCC) is cirrhosis of any etiology, with an annual incidence risk between 1-6%; currently the leading cause of death in patients with cirrhosis and the 2nd cause of…
- Conditions
- Hepatitis C, Cirrhosis, Antiviral Drug Adverse Reaction
- Trial name
- NCT03775798
- Testing
- Direct antiviral agents for hepatitis C
- Where
- Argentina
- Volunteers
- 2,200 people
- Sponsor
- Austral University, Argentina
Hepatitis B, Antiviral Drug Adverse Reaction
Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance
To evaluate the efficacy of switching to tenofovir alafenamide (TAF) 25 mg QD versus continued tenofovir disoproxil fumarate (TDF) 300 mg QD in CHB patients with antiviral resistance, as determined by the proportion of…
- Trial name
- NCT03566030
- Testing
- Tenofovir disoproxil fumarate 300mg, Tenofovir Alafenamide 25 mg
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Antiviral Drug Adverse Reaction
Effect Of DAAs For Treatment Of HCV On Normal Kidney
The aim of the study is to determine the effect of different direct acting antiviral drugs used for treatment of chronic HCV infected patients on normal kidney.
- Trial name
- NCT03296930
- Testing
- Sofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir
- Volunteers
- 100 people
- Sponsor
- Assiut University
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
- Trial name
- NCT02446717
- Testing
- ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530
- Volunteers
- 141 people
- Sponsor
- AbbVie
Hepatocellular Carcinoma, Hepatitis C
Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence
Background and Aims: Arrival of direct-acting antiviral (DAA) agents against hepatitis C virus (HCV) with high-sustained virological response (SVR) rates and very few side effects has drastically changed the management of HCV…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Direct Acting Antivirals
- Trial name
- RECAR (NCT03197155)
- Testing
- Direct Acting Antivirals against hepatitis C virus infection
- Volunteers
- 68 people
- Sponsor
- Hospices Civils de Lyon
HCV Recurrence, Liver Transplantation
Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection
The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence.
- Conditions
- HCV Recurrence, Liver Transplantation, Direct-acting Antiviral Agents
- Trial name
- ANRSCO23CUPILT (NCT01944527)
- Where
- France
- Volunteers
- 699 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis B, Antiviral Treatment
Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B
This open-label study is an roll-over extension of a randomized trial "Efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients with High Viral Load but Slight Aminotransferase Elevation" (NCT01522625).
- Trial name
- NCT02463019
- Testing
- Tenofovir Disoproxil Fumarate
- Volunteers
- 160 people
- Sponsor
- E-DA Hospital
Antiviral Treatment of Chronic Hepatitis B
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Patients with spontaneous decline of HBV DNA were non-randomly assigned to accept peginterferon alfa-2a or entecavir therapy, or didn't accept any antiviral regiment.
- Trial name
- NCT01892241
- Testing
- Pegasys(Roche), Entecavir
- Volunteers
- 74 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University